cGxP.wire https://validator.w3.org/feed/docs/rss2.html Xeltis Raises €20.5M to Advance aXess and US Expansion Pfizer and BioNTech Win EU Approval for XFG COVID-19 Vaccine Vector, Wynn Partner on Critical Care Drug Delivery Seegene Expands Precision Diagnostics for Women’s Health AbbVie Secures EU Approval for RINVOQ in Severe Alopecia Areata Dyne Secures FDA IND Clearance for DYNE-302 in FSHD Evinova and Merck KGaA Partner to Advance AI Clinical Development Alamar Biosciences Launches NULISAseq Immune 340 Panel AGC Biologics Strengthens Global CDMO Leadership MannKind Reports Positive Phase 1b INFLO-1 IPF Results Galmed Advances Brain-Targeted Aramchol for Parkinson’s AbbVie Gains EU Approval for RINVOQ in Vitiligo Care NeuroPace Receives FDA Feedback on IGE PMA Supplement Saol Therapeutics Advances SL1009 in FDA Review Verastem Oncology Doses First Patient in TARGET-D 203 Trial GSK Invests £400M in Cambridge R&D Innovation Centre Altimmune Reports Positive Phase 2 RECLAIM Results for Pemvidutide in Alcohol Use Disorder Knack RCM Unveils AI-Native Anesthesia Revenue Cycle Platform Ambrosia Expands Scientific Leadership in Metabolic Disease GSK Accelerates R&D After Strong Q2 2026 Performance Eisai Grants CORE Exclusive Global Oncology Rights Incyte Secures EU Approval for Opzelura Cream in Atopic Dermatitis IceCure Launches ChoICE Study for ProSense in U.S. Cipla Receives FDA Nod for Generic Advair Diskus CORE Biomedicine Secures $21M Series A Funding TScan Therapeutics Doses First Patient in Phase 3 ALLOHA-2 Trial RedHill Advances Opaganib for Emerging Ebola Outbreak Philips Reports Strong Q2 2026 Growth and AI Innovation Antag Therapeutics Doses First Patient in Phase 2a Trial of AT7687 InnoCare Phase III TYK2 Study Meets Psoriasis Endpoint AbCellera Partners with Vertex to Develop Multispecific T-Cell Engagers C2N Diagnostics Expands PrecivityAD2 Use in UK Alzheimer’s Diagnosis Co-Diagnostics Advances Ebola Testing Innovation Globally Atea Pharmaceuticals Achieves Phase 3 Success in Hepatitis C Trial Cullinan Therapeutics Plans Registrational Phase 2 Trial for CLN-049 ViiV Healthcare Reports Positive Phase IIIb Dovato Results ICON Partners with Anthropic to Transform Clinical Trials with AI Akeso Doses First Patient in HER3 ADC Lung Cancer Trial Guardant Health Launches Patrick Dempsey Campaign for CRC Screening Masimo Earns FDA 510(k) for Pediatric Brain Monitoring Medicus Pharma Receives FDA Clearance for Registrational SkinJect Study Lexicon Pharmaceuticals Completes Enrollment in Phase 3 SONATA-HCM Trial DifGen Wins FDA IND Clearance for Breast Cancer Therapy Revagenix Doses First Patient in Phase 1 Rev-56 Trial Organogenesis Publishes Positive Affinity Trial Results for Venous Leg Ulcers Insilico Medicine Presents ISM6331 Phase 1 Data at ESMO United Therapeutics Reports Phase 3 Ralinepag Results in The Lancet CG Oncology Publishes Positive Phase 3 BOND-003 Results in The Lancet Oncology Ocugen Receives FDA RMAT Designation for OCU410 in Geographic Atrophy Dasher Neuroscience Advances YA-101 Phase 2 Trial